ライブ
Thermo FisherTMO Thermo Fisher Scientific Inc falls 2.95 percent post Q4 2025 earnings despite narrow EPS beat and 3.9 percent year-over-year revenue growth. - Investment Community Signals - UBND thành phố Hải PhòngFierceBiotechLilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitorsThermo FisherThermo Fisher (TMO) Q4 2024 Earnings Transcript - AOL.comWatersWAT (Waters Corporation) rises 1.06 percent after Q4 2025 results, as 7 percent revenue growth offsets minor EPS miss. - Earnings Risk - Cổng thông tin điện tử Tỉnh Sơn LaFierceBiotechMcKesson swaps minority stake in surgical unit to Apollo Funds for $1.25BFierceBiotechAcuityMD raises $80M to help bolster AI in the medtech industryFierceBiotechAACR: NCI leader Letai battles ‘misinformation’ to assure anxious researchers that ‘funding is strong’FierceBiotechMerck goes with Google for AI push, striking enterprise partnership worth up to $1BBioWorldAppointments and advancements for April 22, 2026BioWorldFinancings for April 22, 2026BioWorldIn the clinic for April 22, 2026BioWorldOther news to note for April 22, 2026
BioWorld 2026年2月6日

Bayer’s asundexian cuts stroke risk 26% in phase III win

Bayer’s asundexian cuts stroke risk 26% in phase III win

原文
本文は利用できません。元の情報源をご確認ください。